OTCM
BIXT
Market cap11mUSD
Jun 10, Last price
0.13USD
1D
-2.08%
1Q
-16.77%
IPO
-83.24%
Name
Bioxytran Inc
Chart & Performance
Profile
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 1,280 | 3,828 | 2,138 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (1,280) | (3,828) | (2,138) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (13) | (193) | ||||||||
Tax Rate | ||||||||||
NOPAT | (1,267) | (3,828) | (1,944) | |||||||
Net income | (2,367) -44.70% | (4,280) 73.71% | (2,464) -43.30% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 63 | 550 | 680 | |||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 853 | 1,925 | 2,165 | |||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | 848 | 1,899 | 1,870 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (56) | (775) | (1,806) | |||||||
CAPEX | (32) | |||||||||
Cash from investing activities | (28) | (44) | (32) | |||||||
Cash from financing activities | 63 | 550 | 2,061 | |||||||
FCF | (1,504) | (3,733) | (1,824) | |||||||
Balance | ||||||||||
Cash | 5 | 26 | 295 | |||||||
Long term investments | ||||||||||
Excess cash | 5 | 26 | 295 | |||||||
Stockholders' equity | (18,791) | (16,033) | (11,685) | |||||||
Invested Capital | 17,852 | 14,846 | 10,517 | |||||||
ROIC | ||||||||||
ROCE | 136.31% | 322.57% | 183.07% | |||||||
EV | ||||||||||
Common stock shares outstanding | 138,599 | 134,224 | 115,139 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (602) | (3,820) | (2,134) | |||||||
EV/EBITDA | ||||||||||
Interest | 84 | 542 | 520 | |||||||
Interest/NOPBT |